You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

56 search results for: coexisting diseases

expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

3 min

Dermatology

Dr. Mark Tang talks about the coexistence of AD and PN and considerations for choosing treatment.

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

expert video

How Can We Explore the Concept of Disease Modification in Children With AD?

2 min

Dermatology

Dr. Lawrence Eichenfield discusses the concept of disease modification in children with AD.

expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

12 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, examining how type 2 inflammation influences the neuroimmune axis in prurigo nodularis.

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

28 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.

expert video

Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis

57 min

Dermatology

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region